NCT02636049View on ClinicalTrials.gov

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
End Stage Renal Disease
Interventions
DRUG

Triferic

Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.

Trial Locations (1)

49007

Jasper Clinic, Kalamazoo

All Listed Sponsors
lead

Rockwell Medical Technologies, Inc.

INDUSTRY

NCT02636049 - Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter